Form 8-K - Current report:
SEC Accession No. 0001213900-25-062955
Filing Date
2025-07-11
Accepted
2025-07-11 07:44:43
Documents
13
Period of Report
2025-07-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248655-8k425_helix2.htm   iXBRL 8-K 39462
2 PRESS RELEASE, DATED JULY 11, 2025 ea024865501ex99-1_helix2.htm EX-99.1 20601
  Complete submission text file 0001213900-25-062955.txt   240553

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE hlxb-20250711.xsd EX-101.SCH 3053
4 XBRL LABEL FILE hlxb-20250711_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE hlxb-20250711_pre.xml EX-101.PRE 22384
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0248655-8k425_helix2_htm.xml XML 3814
Mailing Address C/O CORMORANT ASSET MANAGEMENT, LP 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116
Business Address C/O CORMORANT ASSET MANAGEMENT, LP 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 857 702 0377
Helix Acquisition Corp. II (Filer) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41955 | Film No.: 251117506
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)